Second-generation visually guided laser balloon ablation system for pulmonary vein isolation: Learning curve, safety and efficacy ― the MERLIN registry ―

Christian H. Heeger*, Huong Lan Phan, Roza Meyer-Saraei, Thomas Fink, Vanessa Sciacca, Spyridon Liosis, Ben Brüggemann, Niels Große, Bezhad Fahimi, Makoto Sano, Karl Heinz Kuck, Feifan Ouyang, Julia Vogler, Charlotte Eitel, Roland Richard Tilz

*Corresponding author for this work

Abstract

Background: Radiofrequency (RF)-based pulmonary vein isolation (PVI) results in a favorable clinical outcome, although its complexity demands a long learning curve. Balloon-based systems have been developed to possibly solve these limitations. The 2nd-generation laser balloon (LB2) offers optimized features for improved tissue contact and visibility. We determined the safety, efficacy and learning curve of the LB2 for PVI. Methods and Results: A total of 45 consecutive patients (89% persistent AF) were prospectively enrolled and divided into 3 groups (T1, T2, T3) of n=15 patients per group. All patients underwent PVI by 2 operators using the LB2. The operators were experienced in RF and cryothermal procedures, but not in laser ablations. A total of 174/177 PVs (98%) were successfully isolated. The median procedure time significantly declined from 132 (114, 158) to 119 (102, 127) and 91 (86, 105) min in T1–3, respectively (P=0.0009). Similarly, the median fluoroscopy time significantly decreased from T1 to T3 (22 (17, 27) vs. 21 (16, 24) vs. 13 (10, 17) min, respectively, P=0.045). Adverse events occurred in 6.7%, with a trend towards a lower complication rate with increasing experience. Conclusions: The LB2 was safe and effective for PVI, even for operators without any previous experience in laser balloon-based PVI. Procedure time, left atrial dwelling time and fluoroscopy time decreased after a learning curve of 15 cases.

Original languageEnglish
JournalCirculation Journal
Volume83
Issue number12
Pages (from-to)2443-2451
Number of pages9
ISSN1346-9843
DOIs
Publication statusPublished - 25.11.2019

Funding

C.-H.H. received travel grants and research grants from Medtronic, Boston Scientific, Claret Medical, SentreHeart, Biosense Webster and Cardiofocus, and Speaker’s Honoraria from Biosense Webster, Cardiofocus and Boston Scientific. R.R.T. received travel grants from St. Jude Medical, Topera, Biosense Webster, Daiichi Sankyo, and SentreHeart; Speaker’s Bureau Honoraria from Biosense Webster, Biotronik, Pfizer, Topera, Bristol-Myers Squibb; Bayer, and Sano Aventis; and research grants by Cardiofocus. C.E. received travel grants and educational grants from Medtronic. K.H.K. received travel grants and research grants from Biosense Webster, Stereotaxis, Prorhythm, Medtronic, Edwards, and Cryocath, and is a consultant to St. Jude Medical, Biosense Webster, Prorhythm, and Stereotaxis. He received Speaker’s Honoraria from Medtronic. All other authors have no relevant disclosures.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Second-generation visually guided laser balloon ablation system for pulmonary vein isolation: Learning curve, safety and efficacy ― the MERLIN registry ―'. Together they form a unique fingerprint.

Cite this